Gourt > Health > Pharmacy > Drugs and Medications > F > Fulvestrant
Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. It is administered as a once-monthly injection.
Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.
References
Heme/Onc: Activity of fulvestrant in HER2-overexpressing advanced breast cancer: Annals of Oncology http://url4.eu/hjMY (via @MDLinx)
teamoncology ( Naoto T. Ueno (ä¸éç´äºº) Fri, 06 Nov 2009 09:29:30 -0000
Heme/Onc: Activity of fulvestrant in HER2-overexpressing advanced breast cancer: Annals of Oncology http://url4.eu/hjMY (via @MDLinx)
Heme/Onc: Activity of fulvestrant in HER2-overexpressing advanced breast cancer: Annals of Oncology http://url4.eu/hjMY
MDLinx (Sandeep Pulim MD) Fri, 06 Nov 2009 09:16:18 -0000
Heme/Onc: Activity of fulvestrant in HER2-overexpressing advanced breast cancer: Annals of Oncology http://url4.eu/hjMY
500
Faslodex - AstraZeneca - Provides medication information for patients and U.S. healthcare professionals
Faslodex Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.
Fulvestrant - FamilyDoctor.org - Information for patients in English or Spanish.
